GlassScriptPhysician profile
Irim Yasin
NPI 1699921734
$3,550.15
in general payments reported to CMS, 2019-2025
27 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $141 · 2021: $173 · 2022: $222 · 2023: $537 · 2024: $1,423 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.87 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $237.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,623.49 | 2021-2025 | |
| Pfizer INC. | $304.38 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $267.93 | 2020-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $209.77 | 2019-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $198.11 | 2019-2025 | Opdivo |
| Caris Mpi, INC. | $107.84 | 2025 | Mi Cancer Seek |
| Genentech, INC. | $102.02 | 2025 | Itovebi |
| Amgen INC. | $95.77 | 2020-2023 | Lumakras |
| Janssen Biotech, INC. | $86.38 | 2021-2025 | Rybrevant |
| Gilead Sciences, INC. | $77.67 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $63.03 | 2024-2025 | Enhertu |
| Astellas Pharma US INC | $58.28 | 2019-2025 | Padcev |
| Abbvie INC. | $55.37 | 2019-2025 | |
| Lilly USA, LLC | $41.90 | 2019-2020 | |
| Stemline Therapeutics INC. | $38.87 | 2024-2025 | Orserdu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $30.07 | 2023 | Bavencio |
| Beone Medicines USA, INC. | $21.84 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $21.66 | 2023 | Xpovio |
| Sobi, INC | $20.68 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $20.67 | 2019 | |
| Blueprint Medicines Corporation | $19.82 | 2024 | Ayvakit |
| Genentech USA, INC. | $19.81 | 2025 | Polivy |
| Alexion Pharmaceuticals, INC. | $19.61 | 2025 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $18.53 | 2024 | Precisetumor |
| Bayer Healthcare Pharmaceuticals INC. | $13.10 | 2019 | |
| Exelixis INC. | $11.00 | 2019 | |
| Clovis Oncology, INC. | $2.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irim Yasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.